

**BIOLOGICAL ACTIVITY OF RHODIUM METALLOINSERTORS AND  
THE DESIGN OF BIFUNCTIONAL CONJUGATES**

Thesis by

Alyson G. Weidmann

In Partial Fulfillment of the Requirements

for the Degree of

Doctor of Philosophy in Chemistry

California Institute of Technology

Pasadena, CA

2015

(Defended May 28, 2015)

© 2015

Alyson G. Weidmann

All Rights Reserved



## Acknowledgments

First and foremost, I would like to thank my advisor, Professor Jacqueline Barton. You have been an endless source of wisdom, optimism, enthusiasm, and support. My growth as a scientist has been in no small part due to your guidance and example. Your faith in me continued even when I did not have faith in myself, and for that I will always be grateful. It has truly been a privilege to be a member of this lab.

I am deeply thankful to my dissertation committee for being a tremendous source of insight, inspiration, and perspective. To Professor Harry Gray, you have been the most wonderful committee chair; I thank you for all of your advice and guidance. To Professor Brian Stoltz, I am grateful for all of your support and encouragement. I would also like to thank Professor Jonas Peters for your enthusiasm, collegiality, and approachability. I have been so fortunate to have a committee comprised of incredibly creative and knowledgeable faculty who are committed to academic excellence, yet at the same time are down to earth and accessible. Thank you.

I have also had the privilege of working as a teaching assistant for Chem 10. I thank Professor Peter Dervan, whose unparalleled commitment to undergraduate research has served as an example in mentorship. I also thank Professor Andre Hoelz, for your dedication to academic rigor as well as your unmatched sense of humor. It has been great fun TA-ing this class for you both these past four years.

I would also like to thank the people who make the Caltech Chemistry Department run like a well-oiled machine: Agnes Tong, you have been a fantastic Option Administrator as well as an amazing friend. Our Ath lunches hold a special place in my heart. To Mo Renta, thank you for keeping the lab in tip top shape. Thank you to Joe

Drew, Memo, and the rest of the stockroom crew for all that you do, as well as always being down for a good football conversation (thank you for not making too much fun of my beloved New York Giants). Thank you also to Silva Virgil, Amy Woodall-Ojeda, Anne Penney, Steve Gould, and Elisa Brink for always being willing to lend a helping hand. I am also grateful to Mona Shahgholi and Dave VanderVelde – no chemistry would get done without you. Thank you Larry Henling, for diffracting my crystals even though they were crappy. And thank you Felicia Hunt, for always being a friendly face willing to listen.

I am deeply indebted to Nathan Dalleska and the Environmental Analysis Center, without whom half the data in my thesis would simply not exist. Nathan, your endless patience with the ICP-MS instruments has been admirable and invaluable. Thank you for teaching me analytical chemistry (which has, to my delight, involved boiling cancerous human flesh in concentrated acid) as well as how to not take the little things (such as a malfunctioning ball of plasma at 20,000 °C) too seriously.

Thank you to our amazing collaborators for helping to bring our metalloinsertor complexes ever closer to the clinic. Julie Bailis, you have been absolutely wonderful in your diligence and passion for these complexes. Thank you also to Professor Jeremy Stark for your openness to collaboration and creative ideas. I am deeply grateful to Diana Yanez for patiently teaching me immunofluorescence staining and collecting microscopy images. It has been a delight to work with you and I wish you all the best in your M.D.-Ph.D. program. Thank you also to the rest of the Stark Lab, who have welcomed me from Day 1 and have always been a friendly, supportive bunch. I wish your lab all the success in the world.

I must also thank the people from my undergraduate institutions who have played a huge role in my decision to go to grad school: to Columbia University Dean Jim Valentini (Deantini), who got me my first summer research position back when he was head of the Chemistry Department, which changed the course of my life. Thank you also to Professors Koji Nakanishi and Nina Berova of Columbia University, who welcomed me into their lab and taught me magic tricks in addition to chemistry. I am incredibly grateful to Professor JoAnne Stubbe of MIT; your incredible research and group solidified my decision to pursue a Ph.D and inspired me to study bioinorganic chemistry. Thank you also to Joey Cotruvo for your amazing mentorship, and to the rest of the Stubbe lab, for being wonderful co-workers and friends. I am also grateful to the professors who provided guidance and advice to me as an undergraduate: Professor Cathy Drennan, Professor Brent Stockwell (who talked me out of grad school), and Professor Jon Owen (who talked me back into it).

I am incredibly grateful also to my labmates in the Barton laboratory, especially those who took the time to train and teach me. Russ Ernst, you took me under your wing from the very beginning. Your good-naturedness and scientific rigor have been an example to me throughout my graduate career. Thank you also to Curtis Schneider, for teaching me everything I know about synthesis, inorganic chemistry, and beer. And to Alexis Komor, who has been both a great friend as well as an example for me to look up to in lab. I always knew that if I was doing an experiment the way you did it, I was doing it right. Thanks to Jessica Yeung, my incredibly talented former SURF, who continues to amaze me with her dedication and passion for research.

Thank you also to the rest of the Barton lab – all of you have made my time at Caltech a special and unique experience. Natalie Muren, you have always floored me with your unending support and willingness to help or just lend an ear. Phil Bartels, you have been a steadfast worker, an outstanding co-TA, and a true friend. Thank you also to Katie Schaefer, Liz O’Brien, and Anna Arnold for being wonderful co-workers and great sources of conversation and animal videos. A special shout-out to everyone in Subgroup 1, for never making me doubt for a second that I joined the right subgroup: Hang Song, for your optimism and friendliness; Anna McConnell, for all of your synthetic knowledge and sunny disposition; Adam Boynton, for filling the South Side with positivity and sick beatz; and Kelsey Boyle for your rigor and eagerness to learn. It has been a pleasure working with you. I have no doubt that I am leaving Team Rhodium/Ruthenium in the best of hands.

Finally, I must thank the people who truly kept me sane throughout my Ph.D: my amazing friends and family. I would not have gotten through this without your support. Special thanks in particular to Breanne Siegel, Julianna Parapugna, Albert Lee, Andrew Wang, Myles Herbert, Jeremy Kallick, Alex Goldberg, Guy Edouard, Brad Hulse, Mike Post, Jeff Holder, Tim Aarons, Seth Tallob, Ethan van Arnam, Judy Lattimer, Michael van Vliet, Megan McDuffie, and Lina Schaatz. Thank you especially to Tim Mui, who *everybody knows* is a fabulous co-worker (as well as a great friend!).

And to Ariel Furst, my partner in crime, my common-law spouse, my roommate and best friend: without you, I literally would have gone insane. I would have gone batshit, Michael-Jackson-baby-dangling, Britney-Spears-head-shaving, let’s-make-a-Star-Wars-prequel, communism-works-in-theory c-r-a-z-y. From our wine nights and

bad TV to all the amazing trips we've taken, it's been a blast. So thank you for being there for me always, and for keeping me out of the looney bin, and for being the type of friend who would visit me in the looney bin and bring me cheese and contraband. It has been a long road that we've crab-walked, but we've finally made it and now we can adopt a bunch of cats and drink our way through San Francisco. You are a true gem and an incredibly talented chemist, and I am so grateful to have such an amazing friend in my life.

And thank you, truly, to my family, who have unquestioningly supported me throughout this entire process. Mom, Dad, and Danielle, I am so thankful to have you in my life and so honored to have made you proud. I would not be the person that I am, and would not have achieved the success that I have without you. Thank you. I love you.

## Abstract

The Barton laboratory has established that octahedral rhodium complexes bearing the sterically expansive 5,6-chrysene diimine ligand can target thermodynamically destabilized sites, such as base pair mismatches, in DNA with high affinity and selectivity. These complexes approach DNA from the minor groove, ejecting the mismatched base pairs from the duplex in a binding mode termed metalloinsertion. In recent years, we have shown that these metalloinsertor complexes also exhibit cytotoxicity preferentially in cancer cells that are deficient in the mismatch repair (MMR) machinery.

Here, we present evidence to support the notion that mismatches in genomic DNA are the primary biological target of rhodium metalloinsertors and the source of their cell-selectivity. A structure-activity study on a family of ten metalloinsertor complexes revealed a highly sensitive relationship between the lipophilicity of the non-inserting ancillary ligands and the biological activity of the complex. Complexes with hydrophilic ligands were found to be highly cell selective, exhibiting preferential cytotoxicity in MMR-deficient cells at low concentrations and short incubation periods, whereas complexes with lipophilic ligands displayed poor cell-selectivity. ICP-MS studies were carried out to determine the cellular uptake and localization patterns of the ten compounds. The lipophilic complexes displayed enhanced cellular uptake compared to the more polar compounds, and their uptake patterns were indicative of a passive diffusion mechanism. Curiously, there was no correlation between cellular uptake of rhodium and selectivity for MMR-deficient cells. In fact, the complexes with the most selective activity exhibited low cellular accumulation overall. It was also discovered that

all of the complexes localized to the nucleus in concentrations sufficient for mismatch binding; however, highly lipophilic complexes also exhibited high mitochondrial uptake, consistent with the previous study. This relationship between subcellular localization and cell-selective biological activity confirms that mitochondrial DNA is not the desired target of metalloinsertor complexes; rather, these complexes recognize mismatches in genomic DNA.

We have also explored the potential for metalloinsertors to be developed into more complex structures with multiple functionalities that could either enhance their overall potency or impart mismatch selectivity onto other therapeutic cargo. We have constructed a family of bifunctional metalloinsertor conjugates incorporating *cis*-platinum, each unique in its chemical structure, DNA binding interactions, and biological activity. Attachment of a potent oxaliplatin derivative to a metalloinsertor through the leaving group ligand afforded an intrinsically metastable complex with high cytotoxicity in MMR-deficient cancer cells as well as enhanced cellular uptake properties. Additionally, we developed a bimetallic complex derived from a new family of potent and selective metalloinsertors containing an unusual Rh—O axial coordination. This complex also incorporates a platinum center containing only one labile site for coordination of DNA, rather than two, which leads to nonclassical platinum adduct formation selectively at mismatched DNA. Finally, we synthesized a mixed metal dinuclear Rh(III)/Pt(II) complex, wherein both the rhodium and platinum centers are coordinated to a bridging aromatic ligand capable of interaction with the DNA base stack through either intercalation or insertion. These complexes bind DNA mismatches from

the minor groove through metalloinsertion, situating the reactive platinum metal center directly at the mismatched site.

In the development of metalloinsertor-*cis*-platinum conjugates, we have acquired a diverse repertoire of bifunctional complexes with mismatch recognition capability as well as the ability to form covalent adducts. Although we have yet to achieve cell-selective toxicity in MMR-deficient cells, we almost universally observe potency surpassing that of the FDA-approved chemotherapeutic cisplatin in a variety of human cancer cell lines. Moreover, a significant finding in our study of these conjugates has been the discovery that these complexes induce apoptotic cell death, rather than the necrotic pathway typically triggered by rhodium metalloinsertors. It appears that rerouting to the apoptotic pathway is incongruous with the uniquely selective biological activity observed for metalloinsertors. This result suggests that there is a critical response to mismatch recognition in a cellular environment that leads to cell-selective activity.

We further explored the underlying mechanisms surrounding the biological response to mismatch recognition by metalloinsertors in the genome. Immunofluorescence assays of MMR-deficient and MMR-proficient cells revealed that a critical biomarker for DNA damage, phosphorylation of histone H2AX ( $\gamma$ H2AX) rapidly accumulates in response to metalloinsertor treatment, signifying the induction of double strand breaks in the genome. Significantly, we have discovered that our metalloinsertor complexes selectively inhibit transcription in MMR-deficient cells, which may be a crucial checkpoint in the eventual breakdown of the cell via necrosis. Additionally, preliminary *in vivo* studies have revealed the capability of these compounds to traverse the complex environments of multicellular organisms and accumulate in MMR-deficient

tumors. Our ever-increasing understanding of metalloinsertors, as well as the development of new generations of complexes both monofunctional and bifunctional, enables their continued progress into the clinic as promising new chemotherapeutic agents.

**Table of Contents**

<b>Chapter 1: Introduction.....</b>	<b>1</b>
1.1    Overview: Inorganic Complexes as Chemotherapeutic Agents.....	1
1.2    Platinum-Based Chemotherapeutics.....	3
1.2.1    Mechanism of <i>Cis</i> -platinum (II) Activity.....	3
1.2.2    Cisplatin Derivatives and Analogues.....	6
1.3    Targeted Chemotherapy with Metal Complexes.....	8
1.3.1    Proteins as Targets.....	10
1.3.2    Organelles as Targets.....	12
1.4    DNA as a Target: Noncovalent Binding.....	12
1.4.1    Metallointercalators.....	14
1.4.2    Metallointercalators for Selective DNA Recognition.....	19
1.4.3    Metalloinsertors.....	22
1.4.4    Metalloinsertors as Targeted Chemotherapeutics.....	25
1.5    Expanding the Reactivity of Metalloinsertors: Bifunctional Conjugates..	32
1.5.1    Metalloinsertor-Alkylator Conjugate.....	34
1.5.2    Metalloinsertor Conjugate for DNA Cleavage.....	36
1.5.3    Metalloinsertor-Cisplatin Conjugate.....	36
1.5.4    Metalloinsertors Conjugated to Cell-Penetrating Peptides.....	37
1.5.5    Outlook for Bifunctional Metalloinsertor Conjugates.....	38
1.6    Conclusions.....	41
1.7    References.....	43

<b>Chapter 2: Cell-Selective Biological Activity of Rhodium Metalloinsertors Correlates with Subcellular Localization.....</b>	<b>50</b>
2.1 Introduction.....	50
2.2 Experimental Protocols.....	54
2.2.1 Materials.....	54
2.2.2 Ligand Synthesis.....	54
2.2.2.1 Tert-butyl 2-(di(pyridine-2-yl)amino)acetate.....	54
2.2.2.2 2-(di(pyridine-2-yl)amino)ethanol.....	55
2.2.2.3 N-propyl-N-(pyridin-2-yl)pyridin-2-amine.....	55
2.2.3 Metal Complexes.....	57
2.2.3.1 Rh(NH <sub>3</sub> ) <sub>4</sub> chrysi <sup>3+</sup> .....	57
2.2.3.2 <i>rac</i> -Rh(DPAE) <sub>2</sub> chrysi <sup>3+</sup> .....	57
2.2.3.3 <i>rac</i> -Rh(PrDPA) <sub>2</sub> chrysi <sup>3+</sup> .....	59
2.2.4 Octanol/Water Partition Coefficient (log P).....	59
2.2.5 Cell Culture.....	60
2.2.6 Cellular Proliferation ELISA.....	60
2.2.7 Cellular Proliferation MTT.....	60
2.2.8 Binding Competition Titrations.....	61
2.2.9 Whole-Cell Rhodium Accumulation.....	63
2.2.10 Mitochondrial Rhodium Accumulation.....	63
2.2.11 Nuclear Rhodium Accumulation.....	64
2.3 Results.....	65

2.3.1	Synthesis and Characterization of $[\text{Rh}(\text{DPAE})_2\text{chrysi}]^{3+}$ and $[\text{Rh}(\text{PrDPA})_2\text{chrysi}]^{3+}$ .....	65
2.3.2	DNA Binding Affinity.....	66
2.3.3	Cellular Proliferation ELISA.....	68
2.3.4	MTT Cytotoxicity Assay.....	73
2.3.5	Cellular Uptake of Metal Complexes.....	76
2.3.7	ICP-MS Assay for Nuclear Rhodium Levels.....	80
2.3.8	ICP-MS Assay for Mitochondrial Rhodium Levels.....	82
2.4	Discussion.....	83
2.4.1	Biological Activity of Rhodium Metalloinsertors.....	83
2.4.2	Biological Effects of Simple Changes in Functionality on Rhodium Metalloinsertors.....	85
2.4.3	Metalloinsertor Uptake and Nuclear Accumulation.....	87
2.4.4	Mitochondrial Accumulation of Rhodium Metalloinsertors.....	90
2.4.5	General Implications for Design.....	92
2.5	Conclusions.....	94
2.6	References.....	95

<b>Chapter 3: Construction and Application of a Rh-Pt DNA Metalloinsertor Conjugate.....</b>	<b>98</b>	
3.1	Introduction.....	98
3.2	Experimental Protocols.....	99
3.2.1	Materials.....	99

3.2.2	Synthesis of Rhodium Scaffold Precursor.....	100
3.2.2.1	[Rh(HDPA)Cl <sub>4</sub> ]HDPA.....	100
3.2.2.2	[Rh(HDPA)(OTf) <sub>4</sub> ]HDPA.....	101
3.2.2.3	[Rh(HDPA)(NH <sub>3</sub> ) <sub>4</sub> ](OTf) <sub>3</sub> .....	101
3.2.2.4	[Rh(HDPA)(chrysi)(NH <sub>3</sub> ) <sub>2</sub> ](TFA) <sub>3</sub> .....	103
3.2.2.5	[Rh(HDPA)(chrysi)(dpa-AcOH](TFA) <sub>3</sub> .....	103
3.2.3	Synthesis of Rh(Amal) and RhPt.....	104
3.2.3.1	[Rh(HDPA)(chrysi)(diethyl-2-(2-(di(pyridin-2-yl)amino)acetamido)malonate] (TFA) <sub>3</sub> .....	104
3.2.3.2	[Rh(HDPA)(chrysi)(2-(2-(di(pyridin-2-yl)amino)acetamido)-3-ethoxy-3-oxopropanoic acid)] (TFA) <sub>3</sub> ...105	105
3.2.3.3	RhPt.....	105
3.2.4	[Pt(DACH)(aminomalonate)].....	107
3.2.5	Photocleavage Competition Titrations.....	109
3.2.6	Binding Constant Determination.....	110
3.2.7	Dimethyl Sulfate Footprinting of Platinated DNA.....	111
3.2.8	Cell Culture.....	111
3.2.8.1	HCT116N/O.....	111
3.2.8.2	A2780cis.....	112
3.2.9	Cellular Proliferation ELISA.....	112
3.2.10	ICP-MS Assay for Whole-Cell Rh and Pt Levels.....	112
3.2.11	ICP-MS Assay for Nuclear Rh and Pt Levels.....	113
3.2.12	ICP-MS Assay for Mitochondrial Rh and Pt Levels.....	114

3.2.13 MTT Cytotoxicity Assay.....	114
3.2.14 Preparation of Cell Extracts for <i>In Vitro</i> DNA Replication Assay.....	114
3.2.15 <i>In Vitro</i> SV40 DNA Replication Assay.....	116
3.3 Results	
3.3.1 Complexes Synthesized.....	116
3.3.2 DNA Binding Studies.....	118
3.3.2.1 Binding Affinity of Rhodium at a CC Mismatch.....	118
3.3.2.2 Platinum Binding to DNA.....	120
3.3.2.3 Dimethyl Sulfate Footprinting of Pt-DNA Crosslinks.....	120
3.3.3 Quantitation of Inhibition of Cellular Proliferation Using an Enzyme-Linked Immunosorbent Assay (ELISA).....	123
3.3.4 Cell-Free SV40 DNA Replication Assay.....	128
3.3.5 MTT Cytotoxicity.....	129
3.3.6 ICP-MS Assay for Whole-Cell Rhodium and Platinum Levels.....	132
3.3.7 ICP-MS Assay for Nuclear Rhodium and Platinum Levels.....	136
3.3.8 ICP-MS Assay for Mitochondrial Rhodium and Platinum Levels.....	138
3.3.9 Caspase and PARP Inhibition Assays.....	141
3.4 Discussion.....	144
3.4.1 DNA Binding Behavior.....	144
3.4.2 Antiproliferative and Cytotoxic Activity in MMR-Deficient Cells.....	145
3.4.3 Cellular Uptake and Subcellular Localization of Metal Complexes.....	147

3.4.4	Mechanism of Cell Death.....	148
3.5	Conclusions.....	149
3.6	References.....	150

## **Chapter 4: Targeting Platinum to DNA Mismatches via Conjugation to a Metallocinsertor Containing a Rh—O Bond.....153**

4.1	Introduction.....	153
4.2	Experimental.....	159
4.2.1	Materials.....	159
4.2.2	Synthesis of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ .....	159
4.2.3	Photocleavage Competition Titrations.....	160
4.2.4	Binding Constant Determination.....	163
4.2.5	Platinum Binding to Mismatched and Well-Matched Duplex DNA.....	164
4.2.6	Dimethyl Sulfate Footprinting of Platinated DNA.....	165
4.2.7	Cell Culture.....	166
4.2.7.1	HCT116N/O.....	166
4.2.7.2	A2780cis.....	166
4.2.8	MTT Cytotoxicity Assay.....	166
4.2.9	MTT Caspase and PARP Inhibition Assays.....	167
4.3	Results.....	167
4.3.1	DNA Binding Studies.....	168
4.3.1.1	Binding Affinity of Rhodium at a CC Mismatch.....	168
4.3.1.2	Platination of Mismatched and Well-Matched DNA.....	170

4.3.1.3 Dimethyl Sulfate Footprinting of Pt-DNA Crosslinks.....	177
4.3.2 MTT Cytotoxicity Assay.....	178
4.3.3 Caspase and PARP Inhibition Assays.....	182
4.4 Discussion.....	187
4.4.1 Synthesis of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ .....	187
4.4.2 DNA Binding Behavior.....	189
4.4.3 Characterization in Cell Tissue Culture.....	193
4.5 Conclusions.....	194
4.6 References.....	196

**Chapter 5: Synthesis and Characterization of Bimetallic Rh(III)-Pt(II)  
DNA Mismatch Binding Complexes with Bridging Intercalator  
Ligands.....200**

5.1 Introduction.....	200
5.2 Experimental Protocols.....	206
5.2.1 Materials.....	206
5.2.2 Ligand Synthesis.....	207
5.2.2.1 Synthesis of 5,6-dihydrobenzo[ <i>b</i> ][1,10]phenanthroline..	207
5.2.2.2 Synthesis of benzo[ <i>b</i> ][1,10]phenanthroline-5,6-dione....	207
5.2.3 Synthesis of Metal Complexes.....	210
5.2.3.1 $[\text{PtCl}_2(\text{phendione})]$ .....	210

5.2.3.2 $[(bpy)_2Rh(\mu\text{-phendione})PtCl_2]^{3+}$ .....	210
5.2.3.3 $[Rh(bpy)_2bzp]^{3+}$ .....	213
5.2.3.4 $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ .....	213
5.2.4 DNA Binding Behavior.....	217
5.2.4.1 Photocleavage Competition Titration of $[Rh(bpy)_2chrys]^{3+}$ with $[(bpy)_2Rh(\text{phendione})PtCl_2]^{3+}$ .....	217
5.2.4.2 Photocleavage Titration of $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ .....	220
5.2.4.3 Analysis of DNA Binding.....	221
5.3 Results.....	222
5.3.1 Complexes Synthesized.....	222
5.3.2 DNA Binding of $[(bpy)_2Rh(\text{phendione})PtCl_2]^{3+}$ .....	222
5.3.2.1 Binding of $[(bpy)_2Rh(\text{phendione})PtCl_2]^{3+}$ to a CC Mismatch.....	223
5.3.2.2 Covalent Platinum Binding of $[(bpy)_2Rh(\text{phendione})PtCl_2]^{3+}$ to Mismatched and Well-Matched DNA.....	226
5.3.3 DNA Binding of $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ .....	228
5.3.3.1 Binding of $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ to a CC Mismatch.....	228
5.3.3.2 Binding of $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ to a GA Mismatch.....	234
5.3.3.3 Binding of $[(bpy)_2Rh(\mu\text{-bzp})PtCl_2]^{3+}$ to Mismatched and Well- Matched DNA Hairpins.....	236
5.4 Discussion.....	238

5.5	Conclusions.....	244
5.6	References.....	247

## **Chapter 6: Cellular Processing of Rhodium Metallocinsertors:**

### **Investigations into the Underlying Biological Mechanisms Involved in Response to Mismatch**

<b>Recognition.....</b>	<b>250</b>	
6.1	Introduction.....	251
6.2	Experimental Protocols.....	254
6.2.1	Materials.....	254
6.2.2	Cell Culture.....	254
6.2.3	Immunofluorescence Staining of Fixed Cells.....	255
6.2.3.1	Cell Treatment and Fixation.....	255
6.2.3.2	Immunofluorescence Staining.....	255
6.2.3.3	Quantification and Analysis of Fluorescence Images.....	256
6.2.4	MTT Cytotoxicity Assay.....	258
6.2.5	Comet Assay for Damage of Cellular DNA.....	258
6.2.6	Assay for <i>In Cellulo</i> RNA Synthesis in HCT116N and O Cells.....	259
6.2.7	Animals.....	260
6.2.8	Analysis of Tumor Samples for Rhodium Content by ICP-MS.....	261
6.3	Results.....	261
6.3.1	Immunofluorescence Staining of HCT116 Cells.....	261

6.3.1.1	Induction of $\gamma$ H2AX in HCT116 Cells.....	263
6.3.1.2	Induction of 53BP1 in HCT116 Cells.....	271
6.3.2	MTT Cytotoxicity Assay.....	274
6.3.3	Metalloinsertors Induce Double Strand Breaks in the Genome of MMR-deficient Cells: Comet Assay.....	277
6.3.4	Fluorescence Detection of Nascent RNA Synthesis <i>in Cellulo</i> .....	281
6.3.5	Rhodium Accumulation in Tumors.....	282
6.4	Discussion.....	288
6.4.1	Metalloinsertors Damage Genomic DNA.....	288
6.4.2	Metalloinsertors Inhibit Transcription in MMR-Deficient Cells.....	291
6.4.3	Effects of Rhodium Metalloinsertors <i>in Vivo</i> .....	292
6.5	Conclusions.....	293
6.6	References.....	295
<b>Chapter 7: Summary and Outlook.....</b>	<b>299</b>	

## List of Figures, Tables, and Schemes

<b>Figure 1.1</b>	Chemical structures of classical, FDA-approved platinum-based chemotherapeutics.....	2
<b>Figure 1.2</b>	Chemical structures of targeted therapeutics.....	9
<b>Figure 1.3</b>	Design of Octasporine complexes as inhibitors of protein kinases.....	11
<b>Figure 1.4</b>	Chemical structures of octahedral ruthenium (II) tris(phenanthroline) complexes.....	15
<b>Figure 1.5</b>	Chemical structures of $\Delta$ -[Rh(bpy) <sub>2</sub> phi] <sup>3</sup> and $\Delta$ -[Ru(bpy) <sub>2</sub> dppz] <sup>2+</sup> .....	16
<b>Figure 1.6</b>	Rhodium (III) intercalators.....	18
<b>Figure 1.7</b>	Structure of $\Delta$ - $\alpha$ -[Rh[(R,R)-Me <sub>2</sub> trien]phi] <sup>3+</sup> .....	21
<b>Figure 1.8</b>	Comparison of the width of intercalating ligand phi and inserting ligand chrysi.....	23
<b>Figure 1.9</b>	Chemical structures of $\Delta$ -[Rh(bpy) <sub>2</sub> chrysi] <sup>3+</sup> and $\Delta$ -[Rh(bpy) <sub>2</sub> phzi] <sup>3+</sup> .....	26
<b>Figure 1.10</b>	Metalloinsertor DNA binding and cytotoxicity.....	28
<b>Figure 1.11</b>	Effects of the non-inserting ancillary ligands on the biological activity of rhodium metalloinsertors.....	30
<b>Figure 1.12</b>	Inhibitory effects of [Rh(DPAE) <sub>2</sub> chrysi] <sup>3+</sup> and [Rh(PrDPA) <sub>2</sub> chrysi] <sup>3+</sup> on cellular proliferation and subcellular localization.....	31
<b>Figure 1.13</b>	NCI-H23 subclones treated with cisplatin and [Rh(chrysi)(phen)(DPE)] <sup>2+</sup> .....	33
<b>Figure 1.14</b>	Chemical structures of bifunctional, mismatch-specific metalloinsertor conjugates.....	35
<b>Figure 1.15</b>	Structure of a metalloinsertor-peptide conjugate.....	39

<b>Figure 1.16</b> Chemical structures and binding affinities for a CC mismatch of a new family of metalloinsertor complexes bearing Rh—O ligand coordination.....	40
--	----

<b>Figure 2.1</b> Rh(L) <sub>2</sub> chrysi <sup>3+</sup> metalloinsertors. [Rh(DPAE) <sub>2</sub> chrysi] <sup>3+</sup> and [Rh(PrDPA) <sub>2</sub> chrysi] <sup>3+</sup> .....	53
--	----

<b>Figure 2.2</b> Binding affinities determined through DNA photocleavage.....	62
--	----

<b>Figure 2.3</b> Sigmoidal curves for competition titrations with Rh(DPAE) <sub>2</sub> chrysi <sup>3+</sup> and Rh(PrDPA) <sub>2</sub> chrysi <sup>3+</sup> .....	67
---	----

<b>Figure 2.4</b> Chemical structures, binding affinities for CC mismatches, and approximated nuclear concentration of all compounds studied.....	69
---	----

<b>Figure 2.5</b> Inhibitory effects of [Rh(DPAE) <sub>2</sub> chry] <sup>3+</sup> and [Rh(PrDPA) <sub>2</sub> chrysi] <sup>3</sup> as a function of incubation time on cellular proliferation.....	70
---	----

<b>Figure 2.6</b> Inhibitory effects of rhodium metalloinsertors as a function of metalloinsertor identity.....	72
---	----

<b>Figure 2.7</b> Cell viability of HCT116O cells treated with either [Rh(DPAE) <sub>2</sub> chrysi] <sup>3+</sup> or [Rh(PrDPA) <sub>2</sub> chrysi] <sup>3+</sup> over a 24 h period, as determined by MTT assay.....	74
---	----

<b>Figure 2.8</b> Differential cytotoxicities of rhodium metalloinsertors [Rh(DPAE) <sub>2</sub> chrysi] <sup>3+</sup> and [Rh(PrDPA) <sub>2</sub> chrysi] <sup>3+</sup> .....	75
--	----

<b>Figure 2.9</b> ICP-MS assay for rhodium uptake in whole cell extracts.....	77
---	----

<b>Figure 2.10</b> ICP-MS assay for whole-cell rhodium accumulation.....	79
--	----

<b>Figure 2.11</b> ICP-MS assay for nuclear and mitochondrial rhodium accumulation.....	81
---	----

<b>Figure 2.12</b> ICP-MS assay for rhodium uptake in nuclear and mitochondrial fractions.....	86
--	----

<b>Figure 2.13</b> Model for the requirements for cell-selective targeting of MMR-deficient cells by rhodium metalloinsertors.....	93
<b>Figure 3.1</b> Chemical structures of RhPt and control complexes studied.....	117
<b>Figure 3.2</b> Competition titration of of RhPt.....	119
<b>Figure 3.3</b> Representative sigmoidal curve of photocleavage competition titrations of RhPt for binding constant determination at the CC mismatch.....	121
<b>Figure 3.4</b> Representative sigmoidal curve fit of DNA platination by the platinum subunit of RhPt.....	122
<b>Figure 3.5</b> Dimethyl sulfate (DMS) footprinting of RhPt.....	124
<b>Figure 3.6</b> Inhibitory effects of RhPt, oxaliplatin, and cisplatin on cellular proliferation.....	126
<b>Figure 3.7</b> Inhibitory effects of all complexes on cellular proliferation in HCT116O cells after 24 h treatment with 2 $\mu$ M of each complex.....	127
<b>Figure 3.8</b> Cell-free <i>in vitro</i> SV40 replication assay with HCT116O extract.....	130
<b>Figure 3.9</b> Cell-free <i>in vitro</i> SV40 replication assay with Hela cell extract.....	131
<b>Figure 3.10</b> Dose-response cytotoxicity curves of HCT116O cells treated with RhPt, oxaliplatin, Rh(Amal), Pt(Amal), and cisplatin.....	133
<b>Figure 3.11</b> Dose-response cytotoxicity curves of cisplatin-resistant A2780cis cells.....	134
<b>Figure 3.12</b> Cellular accumulation of metal complexes in HCT116O cells.....	137
<b>Figure 3.13</b> Subcellular localization of metal complexes.....	139

<b>Figure 3.14</b> Cell viability in HCT116O cells after 72h with PARP and caspase inhibitors.....	143
<b>Figure 3.15</b> The bifunctional DNA metalloinsertor conjugate (“RhPt”).....	146
<b>Figure 4.1</b> Chemical structures of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ , $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE})]^{2+}$ , and cisplatin.....	158
<b>Figure 4.2</b> ESI-MS spectrum of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ .....	162
<b>Figure 4.3</b> Competition titration of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ at a DNA mismatch.....	169
<b>Figure 4.4</b> Representative sigmoidal curve of photocleavage competition titrations of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ for binding constant determination at the CC mismatch.....	172
<b>Figure 4.5</b> Autoradiogram depicting the formation of covalent platinum adducts with mismatched and well-matched DNA duplexes as a function of time.....	173
<b>Figure 4.6</b> Quantification of platination of mismatched and well-matched duplex DNA by $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ .....	174
<b>Figure 4.7</b> Autoradiogram depicting the formation of covalent platinum adducts with mismatched and well-matched DNA duplexes as a function of metalloinsertor concentration.....	175
<b>Figure 4.8</b> Quantification of platination of mismatched and well-matched duplex DNA (by $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ as a function of concentration.....	176
<b>Figure 4.9</b> Dimethyl sulfate (DMS) footprinting of 5'-end radiolabeled duplex DNA containing a CC mismatch.....	179

<b>Figure 4.10</b> MTT cytotoxicity assay of HCT116N (MMR-proficient) and HCT116O (MMR-deficient) cells treated with $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE}-\text{Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$ , cisplatin, and $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE})]^{2+}$ .....	181
<b>Figure 4.11</b> MTT cytotoxicity assay of cisplatin-resistant A2780cis cells treated with $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE})]^{2+}$ .....	182
<b>Figure 4.12</b> Cell viability in HCT116N and HCT116O cells after treatment with PARP inhibitor DPQ.....	184
<b>Figure 4.13</b> Cell viability in HCT116N and HCT116O cells after treatment with caspase inhibitor Z-VAD-FMK.....	186
<b>Figure 5.1</b> General structures of two distinct families of Rh-Pt metalloinsertor conjugates.....	204
<b>Figure 5.2</b> Chemical structures of two mixed-metal Rh(III)/Pt(II) metalloinsertor complexes, wherein both metal centers are coordinated to the bridging aromatic ligand that interacts with the DNA base stack.....	205
<b>Figure 5.3</b> UV-visible spectrum of $[(\text{bpy})_2\text{Rh}(\mu\text{-phendione})\text{PtCl}_2]^{3+}$ .....	214
<b>Figure 5.4</b> UV-visible spectrum of $[\text{Rh}(\text{bpy})_2\text{bzp}]^{3+}$ .....	216
<b>Figure 5.5</b> UV-visible spectrum of $[(\text{bpy})_2\text{Rh}(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ .....	219
<b>Figure 5.6</b> Photocleavage titration of $[(\text{bpy})_2\text{Rh}(\mu\text{-phendione})\text{PtCl}_2]^{3+}$ .....	224
<b>Figure 5.7</b> Competition titration of $[(\text{bpy})_2\text{Rh}(\mu\text{-phendione})\text{PtCl}_2]^{3+}$ .....	225
<b>Figure 5.8</b> Representative plot of photocleavage competition titrations of $[(\text{bpy})_2\text{Rh}(\mu\text{-phendione})\text{PtCl}_2]^{3+}$ .....	227

<b>Figure 5.9</b> Representative sigmoidal curve fit of DNA platination by the platinum subunit of $[(bpy)_2Rh(\text{phen})\text{PtCl}_2]^{3+}$ .....	229
<b>Figure 5.10</b> Representative exponential curve fit of DNA platination by the platinum subunit of $[(bpy)_2Rh(\text{phen})\text{PtCl}_2]^3$ after 2h incubation.....	230
<b>Figure 5.11</b> Photocleavage titration of $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ at a CC mismatch.....	232
<b>Figure 5.12</b> Quantification of the percentage of DNA containing a CC mismatch that is photocleaved and platinated by $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ .....	233
<b>Figure 5.13</b> Photocleavage titration of $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ at a GA mismatch.....	235
<b>Figure 5.14</b> Photocleavage titration of $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ with mismatched and well-matched DNA.....	237
<b>Figure 5.15</b> Quantification of the percentage of hairpin DNA containing a CC mismatch or is fully matched that is platinated by $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ as a function of complex concentration.....	239
<b>Figure 5.16</b> Quantification of the percentage of platinated CC-mismatched and well-matched DNA by $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ (50 $\mu\text{M}$ ) either in the absence of irradiation or after 15 min irradiation.....	240
<b>Figure 5.17</b> Schematic of hypothesized binding interactions of $[(bpy)_2Rh(\mu\text{-bzp})\text{PtCl}_2]^{3+}$ in the presence of mismatched DNA versus well-matched DNA.....	245

<b>Figure 6.1</b> Chemical structures of $[\text{Rh}(\text{chrysi})(\text{phen})(\text{PPO})]^{2+}$ , $[\text{Rh}(\text{chrysi})(\text{phen})(\text{PPE})]^{2+}$ , $[\text{Rh}(\text{HDPA})_2\text{chrysi}]^{3+}$ , (S)-(+)-Camptothecin, and cisplatin.....	262
<b>Figure 6.2</b> Confocal microscopy of immunofluorescence for $\gamma\text{H2AX}$ .....	264
<b>Figure 6.3</b> Confocal microscopy of dose-dependent immunofluorescence for $\gamma\text{H2AX}$ as a function of rhodium concentration.....	265
<b>Figure 6.4</b> Confocal microscopy of dose-dependent immunofluorescence for $\gamma\text{H2AX}$ as a function of time.....	267
<b>Figure 6.5</b> Quantitation of $\gamma\text{H2AX}$ foci in rhodium-treated HCT116N and HCT116O cells over time.....	268
<b>Figure 6.6</b> Quantitation of $\gamma\text{H2AX}$ -positive HCT116N and HCT116O cells over time treated with rhodium or camptothecin over time.....	270
<b>Figure 6.7</b> Quantitation of $\gamma\text{H2AX}$ foci in untreated or camptothecin-treated HCT116N and HCT116O cells over time.....	272
<b>Figure 6.8</b> Confocal microscopy of immunofluorescence for 53BP1.....	273
<b>Figure 6.9</b> Quantitation of 53BP1 foci in untreated, rhodium treated, or camptothecin-treated HCT116N and HCT116O cells over time.....	275
<b>Figure 6.10</b> Quantitation of 53BP1-positive HCT116N and HCT116O cells over time treated with rhodium or camptothecin over time.....	276
<b>Figure 6.11</b> MTT cytotoxicity assay of HCT116N and HCT116O cells treated with $[\text{Rh}(\text{chrysi})(\text{phen})(\text{PPO})]^{2+}$ and camptothecin.....	278
<b>Figure 6.12</b> Single cell gel electrophoresis of HCT116N and HCT116O cells.....	280

**Figure 6.13** Analysis of RNA synthesis in HCT116N and HCT116O cells as a function of  $[\text{Rh}(\text{chrysi})(\text{phen})(\text{PPO})]^{2+}$  or cisplatin concentration.....283

**Figure 6.14** Rhodium accumulation in human HCT116 tumors harvested from nude mice.....285

**Table 2.1** Qualitative nuclear<sup>a</sup> and mitochondrial<sup>b</sup> uptake properties, as well as the presence or absence of cell-selective biological activity<sup>c</sup> for metalloinsertors.....88

**Table 3.1**  $\text{LC}_{50}$  Values<sup>a</sup> of Metal Complexes in HCT116O and A2780cis Cells.....135

**Table 3.2** Subcellular Distribution of Metal Complexes in HCT116O Cells.....140

**Table 6.1** Antibodies for Immunofluorescence Staining.....257

**Table 6.2** Rhodium Accumulation in HCT116 Tumors.....287

**Scheme 1.1** Thermal activation of cisplatin via associative ligand substitution of the labile chloride ligands with water molecules.....5

**Scheme 2.1** Synthesis of ancillary ligands 2-(di(pyridine-2-yl)amino)ethanol (DPAE) and N-propyl-N-(pyridin-2-yl)pyridin-2-amine (PrDPA).....56

**Scheme 2.2** Synthesis of *rac*- $[\text{Rh}(\text{L})_2\text{chrysi}]^{3+}$  .....58

**Scheme 3.1** Synthesis of rhodium metalloinsertor scaffold for conjugation,  $[\text{Rh}(\text{chrysi})(\text{HDPA})(\text{dpa-AcOH})]^{3+}$  .....102

**Scheme 3.2** Synthesis of conjugate RhPt and its immediate precursor Rh(Amal).....106

**Scheme 3.3** Synthesis of platinum subunit, Pt(Amal).....108

**Scheme 4.1** Synthesis of  $[\text{Rh}(\text{chrysi})(\text{phen})(\text{DPE-Pt}(\text{NH}_3)_2\text{Cl})]^{3+}$  .....161

**Scheme 5.1** Synthesis of 5,6-dihydrobenzo[*b*][1,10]phenanthroline.....208

<b>Scheme 5.2</b>	Synthesis of benzo[ <i>b</i> ][1,10]phenanthroline-5,6-dione.....	209
<b>Scheme 5.3</b>	Synthesis of [PtCl <sub>2</sub> (phendione)].....	211
<b>Scheme 5.4</b>	Synthesis of [(bpy) <sub>2</sub> Rh(μ-phendione)PtCl <sub>2</sub> ] <sup>3+</sup> .....	212
<b>Scheme 5.5</b>	Synthesis of [Rh(bpy) <sub>2</sub> bzp] <sup>3+</sup> .....	215
<b>Scheme 5.6</b>	Synthesis of [(bpy) <sub>2</sub> Rh(μ-bzp)PtCl <sub>2</sub> ] <sup>3+</sup> .....	218

